NEWS

Six-month milestone
The foundations of the ECHoS project are laid and Cancer Mission activities are speeding up in Norway.

Personalising breast cancer screening in Norway
Are polygenic risk scores the answer?

New incubator board member
Thomas London has joined the board of Oslo Cancer Cluster Incubator.

CellFIT workshop in Trondheim
How can manufacturing of T cell therapies be improved?

First demonstration of universal cancer vaccine
New data shows 27% improved survival in the NIPU trial.

Statsbudsjettet 2024
Her er de viktigste sakene i Statsbudsjettet 2024 for Oslo Cancer Clusters medlemmer.

SurViva joins Oslo Cancer Cluster
SurViva is a Norwegian consultancy providing quality guidance for life science companies.

New research on genetic risk and breast cancer
New Norwegian research in polygenic risk score

A roadmap for the health industry
What is the government's ambition for the health industry?